FDA Approval of Genglycos (pariglasgene brecaparvovec-opnr) Gene Therapy, to treat Glycogen Storage Disease Type Ia – Ultragenyx
Ultragenyx Pharmaceutical announced that the FDA granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX 401, in adult and pediatric patients eight years and older with… read more.
